Home › T-Cell Lymphoma › Massachusetts
T-Cell Lymphoma clinical trials in Massachusetts
9 studies for T-Cell Lymphoma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Massachusetts General Hospital, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06561048A Study of Ruxolitinib and Duvelisib in People With Lymphoma
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05010005A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06854653A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05313243A Registry for People With T-cell Lymphoma
- Massachusetts General Hospital (Data Collection Only), Boston
- Dana Farber Cancer Institute (Data Collection Only), Boston
RecruitingObservational study
All ages · All sexes · Updated May 20, 2026 · NCT05978141MB-105 in Patients With CD5 Positive T-cell Lymphoma
- Massachusetts General Hospital, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 3, 2025 · NCT06534060Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.